CalAsia Pharmaceuticals, Inc
Crossing Barriers in Drug Discovery TM
1. Proprietary platform for discovering ‘constraint’ drugs, directed specifically to modulate the activity of chaperone proteins and to cross the blood-brain and ocular barriers. 2. Early stage pipeline extending to pre-clinical stage. 3. Team experienced in discovery of approved drug products, and with globally-recognized strengths in target indications. 4. Predominantly non-dilutive funding to date.